177 related articles for article (PubMed ID: 30659030)
21. Late recurrence of pStage 1 low-grade serous ovarian tumor presenting as a symptomatic bone metastasis: a case report.
Kubo C; Nagata S; Fukuda T; Kano R; Tanaka T; Nakanishi K; Ohsawa M; Nakatsuka SI
Diagn Pathol; 2018 Jun; 13(1):43. PubMed ID: 29960592
[TBL] [Abstract][Full Text] [Related]
22. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary in 18 Patients With Peritoneal Carcinomatosis.
Seidman JD; Savage J; Krishnan J; Vang R; Kurman RJ
Int J Gynecol Pathol; 2020 Jan; 39(1):43-54. PubMed ID: 30480646
[TBL] [Abstract][Full Text] [Related]
24. Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma.
Rollins SE; Young RH; Bell DA
Am J Surg Pathol; 2006 Apr; 30(4):457-62. PubMed ID: 16625091
[TBL] [Abstract][Full Text] [Related]
25. Long term follow-up of a large series of stage-II/III atypical proliferative serous ovarian tumors.
Maria S; Faron M; Maulard A; Pautier P; Leary A; Chargari C; Genestie C; Gouy S; Morice P
Gynecol Oncol; 2020 Sep; 158(3):659-665. PubMed ID: 32571680
[TBL] [Abstract][Full Text] [Related]
26. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
Vang R; Shih IeM; Kurman RJ
Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
[TBL] [Abstract][Full Text] [Related]
27. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns.
Eichhorn JH; Bell DA; Young RH; Scully RE
Am J Surg Pathol; 1999 Apr; 23(4):397-409. PubMed ID: 10199469
[TBL] [Abstract][Full Text] [Related]
28. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary.
Bell KA; Kurman RJ
Am J Surg Pathol; 2000 Nov; 24(11):1465-79. PubMed ID: 11075848
[TBL] [Abstract][Full Text] [Related]
29. Pathologic findings in eight cases of ovarian serous borderline tumors, three with foci of serous carcinoma, that preceded death or morbidity from invasive carcinoma.
Lee KR; Castrillon DH; Nucci MR
Int J Gynecol Pathol; 2001 Oct; 20(4):329-34. PubMed ID: 11603215
[TBL] [Abstract][Full Text] [Related]
30. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
[TBL] [Abstract][Full Text] [Related]
31. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
32. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas.
Bell KA; Smith Sehdev AE; Kurman RJ
Am J Surg Pathol; 2001 Apr; 25(4):419-32. PubMed ID: 11257616
[TBL] [Abstract][Full Text] [Related]
33. Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases.
Gilks CB; Alkushi A; Yue JJ; Lanvin D; Ehlen TG; Miller DM
Int J Gynecol Pathol; 2003 Jan; 22(1):29-36. PubMed ID: 12496695
[TBL] [Abstract][Full Text] [Related]
34. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
[TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).
Singer G; Shih IeM; Truskinovsky A; Umudum H; Kurman RJ
Int J Gynecol Pathol; 2003 Jan; 22(1):37-41. PubMed ID: 12496696
[TBL] [Abstract][Full Text] [Related]
37. Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors.
Bijsmans IT; Smits KM; de Graeff P; Wisman GB; van der Zee AG; Slangen BF; de Bruïne AP; van Engeland M; Sieben NL; Van de Vijver KK
Mod Pathol; 2011 Mar; 24(3):463-70. PubMed ID: 21102419
[TBL] [Abstract][Full Text] [Related]
38. Serous and mucinous borderline (low malignant potential) tumors of the ovary.
Acs G
Am J Clin Pathol; 2005 Jun; 123 Suppl():S13-57. PubMed ID: 16100867
[TBL] [Abstract][Full Text] [Related]
39. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
40. Pathology of ovarian carcinoma.
Seidman JD; Kurman RJ
Hematol Oncol Clin North Am; 2003 Aug; 17(4):909-25, vii. PubMed ID: 12959182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]